Luigi Celio
University of Milan
102 Papers
568 Citations
Luigi Celio is an academic researcher from University of Milan. The author has contributed to research in topics: Palonosetron & Breast cancer. The author has an hindex of 20, co-authored 91 publications.
Chat about Author
Papers
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Claudio Vernieri,Monica Milano,Marta Brambilla,Alessia Mennitto,Claudia Maggi,Maria Silvia Cona,Michele Prisciandaro,Chiara Fabbroni,Luigi Celio,Gabriella Mariani,Giulia Bianchi,Giuseppe Capri,Filippo de Braud +12 more
TL;DR: Defining the best strategies to delay or revert resistance to anti-HER2 treatments will be crucial to improve their clinical efficacy, and only a few mechanisms have been validated in clinical series.
189
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.
Emilio Bajetta,A. Di Leo,Laura Biganzoli,Luigi Mariani,Federico Cappuzzo,M. Di Bartolomeo,Nicoletta Zilembo,S. Artale,E. Magnani,Luigi Celio,Roberto Buzzoni,C. Carnaghi +11 more
TL;DR: VNLB led to a 21% response rate in the population of heavily pretreated and platinum-resistant ovarian cancer patients, and further studies of VNLB alone or in combination with taxanes are warranted in patients with less pretreatment.
144
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon‐alpha‐2a: A study by the Italian trials in Medical Oncology Group
Emilio Bajetta,Nicoletta Zilembo,Maria Di Bartolomeo,Angelo Di Leo,Silvana Pilotti,Anna Maria Bochicchio,Rita Castellani,Roberto Buzzoni,Luigi Celio,Luigi Dogliotti,Gabriella Pinotti,Enrico Aitini,Roberto Labianca,A. Fornasiero,Pietro Riva,Giuseppe Schieppati,P. Nelli,Luigi Mariani +17 more
TL;DR: Using a wide range of interferon doses and schedules, a number of authors have found them to be active against neuroendocrine tumors.
128
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
Luigi Celio,Sergio Frustaci,Angela Denaro,Angela Buonadonna,Antonio Ardizzoia,E. Piazza,Alessandra Fabi,Alba Maria Capobianco,L. Isa,Luigi Cavanna,Alessandro Bertolini,Ettore Bichisao,Emilio Bajetta +12 more
TL;DR: Palonosetron plus single-dose dexamethasone administered before common MEC regimens provide protection against acute and delayed CINV which is non-inferior to that of palonosettron plus dexamETHasone for 3 days, however, the major benefit of the single-day regimen occurs in patients receiving non-AC M EC regimens.
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
Emilio Bajetta,Nicoletta Zilembo,Mitchell Dowsett,L Guillevin,A. Di Leo,Luigi Celio,Antonia Martinetti,A. Marchianò,P. Pozzi,S Stani,Ettore Bichisao +10 more
TL;DR: In this paper, a double-blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5mg orally daily, in postmenopausal advanced breast cancer patients progressing after tamoxifen.
79